TNF-blocking therapies: an alternative mode of action?

Choo-Kang, B., Hutchison, S., Nickdel, M., Bundick, R., Leishman, A., Brewer, J., McInnes, I. and Garside, P. (2005) TNF-blocking therapies: an alternative mode of action? Trends in Immunology, 26, pp. 518-522. (doi:10.1016/j.it.2005.07.007) (PMID:16087401)

Full text not currently available from Enlighten.

Abstract

Despite expanding use of drugs blocking tumour necrosis factor (TNF), their precise mechanisms of action remain unclear. Early assumptions that they act by direct neutralization of the toxic inflammatory effects of TNF might be too simplistic because they explain neither the range of effects observed nor the varying properties of different TNF-blocking agents. Recent studies have demonstrated a key role for mast cell-derived TNF in the increase in lymph node size and the organizational complexity that accompanies a developing immune response. Regulation of this phenomenon might comprise a novel mode of action for TNF-directed therapy: by preventing this lymph node hyperplasia, TNF blockade could modulate immune responses, ameliorating pathology in autoimmune diseases, such as rheumatoid arthritis.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:McInnes, Professor Iain and Garside, Professor Paul and Brewer, Professor James
Authors: Choo-Kang, B., Hutchison, S., Nickdel, M., Bundick, R., Leishman, A., Brewer, J., McInnes, I., and Garside, P.
College/School:College of Medical Veterinary and Life Sciences
College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Trends in Immunology

University Staff: Request a correction | Enlighten Editors: Update this record